Just got mine too!, Inside front cover and facing page also colorful Vascepa Ad. They are doing the right things, just matter of time.
Sentiment: Strong Buy
I called up AMRN, drug rep showed up 3 days latter.
Sentiment: Strong Buy
Don't forget, Vascepa is taken 2 pills twice a day, so it wouldn't be divided into 4 doses. It is true statins should be taken at night as most cholesterol synthesis takes place at night. We'll have to see how AMRN did combo studies.
Sentiment: Strong Buy
Great link! Email to to all Pharmacies dated today. First I have heard of CVS/Caremark being on board. Also includes AARP.
Sentiment: Strong Buy
1000 Doc's got 5 bottles so at least 5000 patients were, will be, started on Vascepa. Each bottle has 120 or a months supply. Patients get Vascepa directly from Doc, no Pharmacy involved on sample bottle. Now I would guess Doc's gave Rx to patients at time but most patients will try Vascepa sample for a month before filling Rx.
Sentiment: Strong Buy
Agree, very important study. I think reasonable at this time that Diabetics with Tri over 150 should all be on Vascepa (and statin) until results of REDUCE-IT come in! I believe JELIS will prove true in our population.
Sentiment: Strong Buy
I think it was a fine idea but, as Churchill's party said of Gallipoli, it was a fine idea but it just didn't work! FDA may be waiting for official start date of May 1. I've been buying current months $10 Calls for a nickel few days before OB every month, may skip April, wait for May!
Sentiment: Strong Buy
Most recent magazine lead story on Obesity Epidemic. Half way through article is 3 page Vascepa, colorfull ad. Great placement by AMRN. Circulation 170,000, sent free to most Docs.
Sentiment: Strong Buy
Good post K, When the majority of Doc's learn about ANCHOR and see the possibilities of JELLIS good things will happen for Vascepa.
Sentiment: Strong Buy
You mean AZN hasn't approached you for site buyout yet! LOL PS: great anticipation on your part to grab site!
Sentiment: Strong Buy
Best possible combo pill for heart disease and/or CV risk factors! Even if say PFE buys AMRN to rejuvinate Lipitor, I think some doc's would Rx Crestor and Vascepa separately.
Sentiment: Strong Buy
Good point! I saw on blogs last fall sometime that AZN had applied for trade name "Crestepa". AZN's Crestor is most powerful statin on market, Also recent study showed good reduction in CRP (inflammation marker). I also believe AZN's patent on Crestor runs out in few years!
Sentiment: Strong Buy
I hope all AMRN longs read this SA articke. DrRx, author, seems to really know what he's talking about. One of best articles I've seen!!. Fine DD
Sentiment: Strong Buy
AK, Because you were a "sentinel" back in '85 may be the reason you are here with us today. Castelli and Framingham Heart Study didn't come out 'till '88, thats when medicine became enlightened on cholesterol! My compliments for being a go getter on your own health!
Medicine loves formulas and ratios, they usually work good but occasionally show association without cause and effect. Niacin raises HDL by 25% and lowers tri by 25%, and LDL by 8%. Does wonderful things for ratio but not for CV outcomes.
I don't agree that PLUSEPA can be substituted for Vascepa, maybe, maybe not. PLUSEPA 90% EPA, Vascepa 96%, the extra 6% of DHA or other contaninents could block some of EPA's good effects! Only outcomes study on PLUSEPA could prove equality with Vascepa. The problem with health insurance and managed care is money, you pay for PLUSEPA, they would have to pay for Vascepa if covered!
Most of the med people I know get MPR for free every month, have for years. If pd subscriptions are 400K, actual distribution must be huge. It's an excellent quick reference used everyday!
Sentiment: Strong Buy
I agree with cardios who have doubts about heart benefits of lowering tri less than 500. Fibrates and Niacin don't have solid data on on doing good things for cardio (recent Niacin study). I do believe that Jellis will prove true with Reduce-It, not because of tri lowering, but because of lowering other lipid subtypes and inflammaton decrease.
Sentiment: Strong Buy